Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-29

Clinical Trial Update: Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept [Phase 4]

View source ↗

Summary

Clinical trial update for intravitreal brolucizumab in neovascular age-related macular degeneration with limited response to aflibercept; study terminated in Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Brolucizumab (brolucizumab)

Snippet

Sponsor: Vista Klinik | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: TERMINATED